Relugolix, as an effective GnRH receptor antagonistic drug, has demonstrated the optimized drug therapy effect and security when it was made use of in the process of treating bleeding in menstruation and estrogen-associated pain in UF and endometriosis. This evidence concerns the gene GNRHR and endometriosis.